Peter ten Dijke

Peter ten Dijke is a Professor in Molecular Cell Biology at Leiden University (The Netherlands) and section head at the Department of Cell and Chemical Biology, Leiden University Medical Center. He obtained his MSc and PhD at Wageningen University, conducting doctoral research at Oncogene Science Inc. His career spans institutions including the Ludwig Institute for Cancer Research, Netherlands Cancer Institute, and Oncode Institute.

• Education: MSc and PhD at Wageningen University (Netherlands), PhD research at Oncogene Science Inc.
• Past Positions: Visiting Professor at Norwegian University of Science and Technology (2005-2009), Head of Division Cellular Biochemistry at Netherlands Cancer Institute (2003-2004), and roles at Ludwig Institute for Cancer Research (1994-1999).

Research Focus: Ten Dijke investigates transforming growth factor-β (TGF-β) signaling pathways and their roles in inter/intra-cellular communication, cancer, bone disorders, and cardiovascular diseases. His work includes identifying TGF-β receptors, SMAD transcription factors, and SMAD7 inhibitors, leading to novel drug targets.

Scientific Awards:

• 2018 Member of Royal Netherlands Academy of Arts and Sciences (KNAW)
• 2016 EMBO member
• 2006 VICI grant (Netherlands Organization for Scientific Research)
• 2005 Honorary Doctor of Medicine, Uppsala University
• Multiple visiting professorships

Patents: Holds two granted patents related to activin-like receptor antibodies and SMAD7 identification. His research integrates chemistry and biology to develop synthetic drug molecules for unmet medical needs.